Investigation of Nasal Mucosal IgA Responses in the Population Following COVID-19 Pandemic — China, September 2022

Investigation of Nasal Mucosal IgA Responses in the Population Following COVID-19 Pandemic — China, September 2022–August 2023

Published:2024 Issue:15 Volume:6 Page:312-317
ISSN:2097-3101
Container-title:China CDC Weekly
language:en
Short-container-title:

Author:

Li Boyang, ,Zhou Lei,Chen Zhilong,Wen Yanhan,Wang Qian,Huang Tao,Chen Si,Wu Wei,Wang Mengxuan,Sun Lina,Liang Mifang,Wang Shiwen,Chen Ling,Li Qun, , , ,

Publisher

Chinese Center for Disease Control and Prevention

Link

https://weekly.chinacdc.cn/en/article/pdf/preview/10.46234/ccdcw2024.060

Reference9 articles.

1. Marking U, Bladh O, Havervall S, Greilert-Norin N, Gordon M, Alm JJ, et al. Mucosal IgA protects against BQ. 1 and BQ.1.1 infection. Lancet Infect Dis 2023;23(8):e272 − 3. https://doi.org/10.1016/s1473-3099(23)00421-8.

2. Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine 2023;87:104402. https://doi.org/10.1016/j.ebiom.2022.104402.

3. Marking U, Bladh O, Havervall S, Svensson J, Greilert-Norin N, Aguilera K, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect Dis 2023;23(2):150 − 2. https://doi.org/10.1016/s1473-3099(22)00834-9.

4. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. Geneva (Switzerland): World Health Organization; 2020. https://iris.who.int/handle/10665/330893.

5. Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med 2022;387(14):1333 − 6. https://doi.org/10.1056/NEJMc2209651.